Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Lars Mjörnstedt"'
Autor:
Lillian Streichart, Marie Felldin, Jana Ekberg, Lars Mjörnstedt, Per Lindnér, Annette Lennerling, Verena Bröcker, Johan Mölne, Jan Holgersson, Kristien Daenen, Lars Wennberg, Tomas Lorant, Seema Baid-Agrawal
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-15 (2024)
Abstract Background Chronic active antibody-mediated rejection (caAMR) in kidney transplants is associated with irreversible tissue damage and a leading cause of graft loss in the long-term. However, the treatment for caAMR remains a challenge to dat
Externí odkaz:
https://doaj.org/article/44ba75643e6d4314bde9aee06803a006
Autor:
Pierre Larsson, Bodil Englund, Jana Ekberg, Marie Felldin, Verena Broecker, Lars Mjörnstedt, Seema Baid-Agrawal
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 20, p 6667 (2023)
All chronic and treatment-resistant acute rejections are “difficult-to-treat” and lead to progressive loss of graft function in kidney transplant recipients (KTR), as no effective treatment exists for such rejections to date. We review our experi
Externí odkaz:
https://doaj.org/article/633e6379202b4810ae07178a0745aef4
Autor:
Obbo W. Bredewold, MD, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström
Publikováno v:
Kidney Medicine, Vol 5, Iss 1, Pp 100574- (2023)
Rationale & Objective: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)–based regimens. Our obje
Externí odkaz:
https://doaj.org/article/c79dbfeee8274a49bb87981258c2c2b4
Autor:
Obbo W. Bredewold, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström
Publikováno v:
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A-J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, Fijter, J W D, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sörensen, S S, van Zonneveld, A J & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, Fijter, J W D, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sörensen, S S, van Zonneveld, A J & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
RATIONALE & OBJECTIVE: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. Our object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69b94a611d7a310d374c44136f21cf6
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498007
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498007
Autor:
Obbo W. Bredewold, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Sören S. Sörensen, Anton-Jan Zonneveld, Bengt Fellstrom
In renal transplant recipients (RTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. The aim of this randomized, multi-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eac222c1e58682c102b6e3108952dd8
https://doi.org/10.21203/rs.3.rs-1283060/v1
https://doi.org/10.21203/rs.3.rs-1283060/v1
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Kidney transplantation is a frequent treatment in uremic patients. However, long term patency is limited. The aim of this study was to investigate the histological findings in transplant biopsies in relation to clinical outcome in
Publikováno v:
CRC Handbook of Microsurgery ISBN: 9780429265846
CRC Handbook of Microsurgery
CRC Handbook of Microsurgery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::622e03e7ac8a89807f37e726722daa4c
https://doi.org/10.1201/9780429265846-49
https://doi.org/10.1201/9780429265846-49
Autor:
Jonas Wadström, Markus Gäbel, Gunnar Tydén, Persson Nh, Jan Tollemar, Lars Mjörnstedt, Henrik Ekberg, Helena Genberg, Gunnar Tufveson
Publikováno v:
Transplantation. 87:1325-1329
We performed a prospective, double blind, randomized, placebo-controlled multicenter study on the efficacy and safety of rituximab as induction therapy, together with tacrolimus, mycophenolate mofetil, and steroids. The primary endpoint was defined a
Publikováno v:
Clinical Transplantation. 22:366-371
In a single-center study, 20 kidney transplant patients without prior rejection were abruptly converted from cyclosporine to everolimus at seven wk post-transplant. All patients received basiliximab induction with maintenance enteric-coated mycopheno
Autor:
D. Solbu, Claus Bistrup, Helene Andersson, Bengt Gustafsson, Jesper Melchior Hansen, Bengt von zur Mühlen, Lars Mjörnstedt, Bente Jespersen, Søren Schwartz Sørensen, Hallvard Holdaas
Publikováno v:
Mjörnstedt, L, Schwartz Sørensen, S, von Zur Mühlen, B, Jespersen, B, Hansen, J M, Bistrup, C, Andersson, H, Gustafsson, B, Solbu, D & Holdaas, H 2015, ' Renal function three years after early conversion from a calcineurin inhibitor to everolimus : results from a randomized trial in kidney transplantation ', Transplant International, vol. 28, no. 1, pp. 42-51 . https://doi.org/10.1111/tri.12437
Mjörnstedt, L, Schwartz Sørensen, S, von Zur Mühlen, B, Jespersen, B, Hansen, J M, Bistrup, C, Andersson, H, Gustafsson, B, Solbu, D & Holdaas, H 2015, ' Renal function three years after early conversion from a calcineurin inhibitor to everolimus : results from a randomized trial in kidney transplantation ', Transplant international : official journal of the European Society for Organ Transplantation, vol. 28, no. 1, pp. 42-51 . https://doi.org/10.1111/tri.12437
Mjörnstedt, L, Schwartz Sørensen, S, von Zur Mühlen, B, Jespersen, B, Hansen, J M, Bistrup, C, Andersson, H, Gustafsson, B, Solbu, D & Holdaas, H 2015, ' Renal function three years after early conversion from a calcineurin inhibitor to everolimus : results from a randomized trial in kidney transplantation ', Transplant international : official journal of the European Society for Organ Transplantation, vol. 28, no. 1, pp. 42-51 . https://doi.org/10.1111/tri.12437
Summary In a 36-month, open-label, multicenter trial, 202 kidney transplant recipients were randomized at week 7 post-transplant to convert to everolimus or remain on cyclosporine: 182 were analyzed to month 36 (92 everolimus, 90 controls). Mean (SD)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8013f8d6ab68fef9f774244b1d482f32
https://pure.au.dk/portal/da/publications/renal-function-three-years-after-early-conversion-from-a-calcineurin-inhibitor-to-everolimus(73c44c36-9b03-44c7-a2b7-17fbda919257).html
https://pure.au.dk/portal/da/publications/renal-function-three-years-after-early-conversion-from-a-calcineurin-inhibitor-to-everolimus(73c44c36-9b03-44c7-a2b7-17fbda919257).html